Lyra Therapeutics, Inc.LYRANASDAQ
Loading
EV to Sales: Discounted ValuationCompressed
Percentile Rank33
3Y CAGR-64.6%
Year-over-Year Change
Enterprise value to sales ratio
3Y CAGR
-64.6%/yr
Annual compound
Percentile
P33
Within normal range
vs 3Y Ago
0x
Contraction
Streak
1 yr
Consecutive declineCompressed
| Period | Value | YoY Change |
|---|---|---|
| 2024 | 434.01 | -94.8% |
| 2023 | 8368.41 | +141.7% |
| 2022 | 3461.94 | -64.6% |
| 2021 | 9777.81 | - |
| 2020 | 0.00 | - |
| 2019 | 0.00 | -100.0% |
| 2018 | 4655.46 | - |